The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet medical needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in Pharmaceuticals: Peptide-based compositions for Alzheimer’s Disease.  Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. 

Peptide-based compositions for Alzheimer’s Disease is a key innovation area in biosimilars 

Alzheimer’s Disease (AD) is a form of dementia and the most common progressive neurodegenerative disease (ND). Although amyloid-beta (Aβ) has long been used as a potential target for managing AD, the use of peptide-based compounds is under investigation globally for the early diagnosis and treatment of AD. Studies in mouse model have demonstrated significant improvement the mice’s memory with two short peptides injected daily for five weeks. The treatment also reduced some of the disease-associated harmful physical changes in the brain. 

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 70+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of peptide-based compositions for Alzheimer’s Disease. 

Key players in peptide-based compositions for Alzheimer’s Disease – a disruptive innovation in the pharmaceutical industry  

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators. 

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’. 

Patent volumes related to peptide-based compositions

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
AC Immune 143 Unlock Company Profile
F. Hoffmann-La Roche 125 Unlock Company Profile
Forschungszentrum Julich 89 Unlock Company Profile
AbbVie 86 Unlock Company Profile
Pfizer 83 Unlock Company Profile
Axon Neuroscience 80 Unlock Company Profile
UCB 72 Unlock Company Profile
Eli Lilly and 70 Unlock Company Profile
Abbott Laboratories 54 Unlock Company Profile
United Biomedical 53 Unlock Company Profile
Biogen 50 Unlock Company Profile
Teijin 46 Unlock Company Profile
Perrigo 46 Unlock Company Profile
Eisai 44 Unlock Company Profile
Sanofi 41 Unlock Company Profile
BioArctic 40 Unlock Company Profile
Johnson & Johnson 36 Unlock Company Profile
Massachusetts General Hospital 34 Unlock Company Profile
National Research Council of Canada 29 Unlock Company Profile
Grifols 28 Unlock Company Profile
Lundbeck Foundation 26 Unlock Company Profile
Sangamo Therapeutics 25 Unlock Company Profile
Nymox Pharmaceutical 23 Unlock Company Profile
Bristol-Myers Squibb 22 Unlock Company Profile
MorphoSys 20 Unlock Company Profile
Alnylam Pharmaceuticals 17 Unlock Company Profile
Proclara Biosciences 17 Unlock Company Profile
Alzinova 16 Unlock Company Profile
General Hospital 14 Unlock Company Profile
Intellect Neurosciences 14 Unlock Company Profile
TauRx Pharmaceuticals 14 Unlock Company Profile
Cedars-Sinai Health System 13 Unlock Company Profile
Tao Health Life Pharma 13 Unlock Company Profile
Priavoid 12 Unlock Company Profile
AFFiRiS 12 Unlock Company Profile
Vitruvian Biomedical 12 Unlock Company Profile
HU Group Holdings 12 Unlock Company Profile
Prothena 11 Unlock Company Profile
Vivoryon Therapeutics 11 Unlock Company Profile
Meiji Holdings 11 Unlock Company Profile
Kaketsuken 10 Unlock Company Profile
Adlyfe 10 Unlock Company Profile
Nederlanden Staat 10 Unlock Company Profile
Proteome Sciences 9 Unlock Company Profile
Vaxxinity 9 Unlock Company Profile
Mercia Pharma 9 Unlock Company Profile
Jiangsu Nuo-Beta Pharmaceutical Technology 9 Unlock Company Profile
Emergent BioSolutions 9 Unlock Company Profile
Nestle 9 Unlock Company Profile
Sumitomo Chemical 8 Unlock Company Profile

Source: GlobalData Patent Analytics

AC Immune, one of the leading players, is utilising its technology platforms SupraAntigen and Morphomer to fuel its broad and diversified pipeline of first and best-in-class assets. The company partners with pharmaceutical majors such as Genentech (Roche Group), Eli Lilly, and Janssen Pharmaceuticals (Johnson & Johnson group) to develop anti-Aβ and anti-tau antibodies using its proprietary technologies.

Roche, which is known for its cancer medicines and diagnostics, has built up its AD pipeline by collaborating with MorphoSys to develop gantenerumab, which is now in Phase III clinical trials for AD. Roche has further expanded its AD pipeline via its subsidiary, Genentech, through licensing agreements with other companies. At the same time, Genentech is developing anti-Aβ and anti-tau antibodies using AC Immune’s proprietary SupraAntigen technology platform.

In terms of application diversity, Alnylam Pharmaceuticals is the top company, followed by Proteome Sciences and Vitruvian Biomedical. By means of geographic reach, Teijin holds the top position. MorphoSys and Alnylam Pharmaceuticals are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.